IL-23 pathway inhibitors
Immunology· 5 reviewed drugs· 14142 cited findings behind them
What the regulatory reviews cover
The IL-23 pathway inhibitors reviewed in this library include Tremfya, Skyrizi, Omvoh, Stelara, and tildrakizumab. These drugs have been reviewed for indications such as active psoriatic arthritis, moderately to severely active ulcerative colitis, and moderate to severe plaque psoriasis in adults.
Regulatory reviews have reported various outcomes. For Tremfya, the Clinical remission (primary endpoint) showed statistically significant results. Skyrizi demonstrated an sPGA 0 or 1 response rate (%) of 61. Omvoh's review noted a Clinical Remission at Week 12 of 23.5, compared to 13.9 for Placebo. For tildrakizumab, the PASI 75 response rate was 63.8, compared to 5.8 for the comparator. It is important to note that different drugs were studied in different trials, and therefore, these figures are not directly comparable head-to-head.
The drugs — one cited result each
| Tremfya Johnson & Johnson | Clinical remission (primary endpoint): statistically significant results JANSSEN BIOTECH — Tremfya FDA Review, p.110 |
| Skyrizi AbbVie Inc. | sPGA 0 or 1 response rate (%): 61 ABBVIE INC — Skyrizi FDA Review (NDA/BLA 761105, 2024), p.21 |
| Omvoh Eli Lilly and Company | Clinical Remission at Week 12: 23.5 Eli Lilly and Company — Omvoh FDA Review (BLA761279, ORIG 1,, p.130 |
| Stelara Johnson & Johnson | Clinical Response at Week 6 (Induction Study 3001): 34.3 % Johnson & Johnson — Stelara FDA Review (BLA761044, ORIG 1, 2, p.113 |
| tildrakizumab Almirall S A | PASI 75 response rate (tildrakizumab): 63.8 Almirall S A — Ilumetri EMA EPAR public assessment report (E, p.50 |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Immunology research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.